Comparison of classical and non-classical cardiovascular risk factors influencing the patency of native arteriovenous fistulas after percutaneous transluminal angioplasty therapy among haemodialysis patients

Postgraduate Medical Journal

Volumn 83, Issue 982, 2007, Pages 547-551

  Liu, Jiung Hsiun ^a   Lin, Po Wen ^a   Liu, Yao Lung ^a   Lin, Hsin Hung ^a   Huang, Chiu Ching ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM PHOSPHATE; PARATHYROID HORMONE;

ADULT; ALBUMIN BLOOD LEVEL; ARTERIOVENOUS FISTULA; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARTERIOVENOUS ANASTOMOSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CATHETERS, INDWELLING; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR PATENCY;

EID: 34548176570     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.054908     Document Type: Article

References (28)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for vascular access. Am J Kidney Dis 2001;37(suppl 1):S137-81.
2. Maeda K, Furukawa A, Yamasaki M, et al. Percutaneous transluminal angioplasty for Brescia-Cimino hemodialysis fistula dysfunction: technical success rate, patency rate and factors that influence the results. Eur J Radiol 2005;54:426-30.
3. Goldwasser P, Avram MM, Collier JT, et al. Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis 1994;24:785-94.
4. Lazarides MK, Latrou CE, Karanikas ID, et al. Factors affecting the lifespan of autologous and synthetic arteriovenous access routes for hemodialysis. Eur J Surg 1996;162:297-301.
5. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-62.
6. Urso S, Milone F, Garozzo M, et al. Cardiovascular risk markers in hemodialysis. G Ital Nefrol 2004;21(suppl 30):S212-6.
7. Gray RJ, Sacks D, Martin LG, et al. Reporting standards for percutaneous interventions in dialysis access. Technology Assessment Committee. J Vasc Interv Radiol 1999;10:1405-15.
8. Owen WF, Lew N, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001-6.
9. Drexel H, Steurer J, Muntwyler J, et al. Predictors of the presence and extent of peripheral arterial occlusive disease. Circulation. 1996;94: II 199-205, (suppl 9).
10. Cohen DJ, Doucet M, Cutlip DE, et al. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox? Circulation 2001;104:773-8.
11. st year after lower-limb endovascular interventions. Radiology 2004;231:831-8.
12. Togane Y, Morita T, Suematsu M, et al. Protective role of endogenous carbon monoxide in neointimal development elicited by arterial injury. Am J Physiol Heart Circ Physiol 2000;278:H623-32.
13. Orford JL, Selwyn AP, Ganz P, et al. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000;86(suppl):6H-11.
14. Ambalavanan N, Carlo WF, Bulger A, et al. Effects of cigarette smoke extract on neonatal porcine vascular smooth muscle cells. Toxicol Appl Pharmacol 2001;170:130-6.
15. Tonelli M, Hirsch D, Clark TW, et al. Access flow monitoring of patients with native vessel arteriovenous fistulae and previous angioplasty. J Am Soc Nephrol 2002;13:2969-73.
16. Polkinghorne KR, Atkins RC, Kerr PG. Native arteriovenous fistula blood flow and resistance during hemodialysis. Am J Kidney Dis 2003;14:3264-9.
17. Besarab A, Lubkowski T, Vu A, et al. Effects of systemic hemodynamics on flow within vascular accesses used for hemodialysis. ASAIO J 2001;47:501-6.
18. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D and cardiovascular disease in chronic renal failure. Kidney Int 1999;56:383-92.
19. Grandaliano G, Teutonico A, Allegretti A, et al. The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. Kidney Int 2003;64:715-9.
20. Drueke TB, Massy ZA. Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. Blood Purif 2002;20:494-7.
21. Little WC, Downes TR, Applegate RJ. The underlying coronary lesion in myocardial infarction: implications for coronary angiography. Clin Cardiol 1991;14:868-74.
22. Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992;69:729-32.
23. Van der wal AC, Becker AE, Van der loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaaues is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
24. Pasterkamp G, Schoneveld AH, Van der wal AC, et al. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. Arterioscler Thromb Vasc Biol 1999;19:54-8.
25. Boyle JJ. Association of coronary plaque rupture and atherosclerotic inflammation. J Pathol 1997;181:93-9.
26. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998;9:2368-76.
27. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001;19:53-61.
28. Revanur VK, Jardine AG, Hamilton DH, et al. Outcome of arterio-venous fistula at the elbow for hemodialysis. Clin Transplant 2000;14:318-22.